{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:17:25Z","timestamp":1793657845054,"version":"4.5.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA263301-01A1"],"award-info":[{"award-number":["CA263301-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["1039927"],"award-info":[{"award-number":["1039927"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41591-024-03040-4","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:04:10Z","timestamp":1718345050000},"page":"1655-1666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-0677","authenticated-orcid":false,"given":"Adam J.","family":"Widman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-5421","authenticated-orcid":false,"given":"Amanda","family":"Frydendahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole C.","family":"Khamnei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"\u00d8gaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushri","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Quentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-8877","authenticated-orcid":false,"given":"Jake","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theophile","family":"Langanay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0223-3401","authenticated-orcid":false,"given":"Laura","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Steinsnyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-4694","authenticated-orcid":false,"given":"Will","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-6303","authenticated-orcid":false,"given":"Mads Heilskov","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenna Vesterman","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-3362","authenticated-orcid":false,"given":"Sarah \u00d8strup","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-7263","authenticated-orcid":false,"given":"Jesper","family":"Nors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-6986","authenticated-orcid":false,"given":"Christina","family":"Therkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-6647","authenticated-orcid":false,"given":"Ryan","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-1438","authenticated-orcid":false,"given":"Joshua S.","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-6213","authenticated-orcid":false,"given":"Ronak H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-0992","authenticated-orcid":false,"given":"Alexandre Pellan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-9272","authenticated-orcid":false,"given":"Colleen","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3355-5267","authenticated-orcid":false,"given":"Dennie T.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendie","family":"den Brok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lohrisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Shenkier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-2742","authenticated-orcid":false,"given":"Andrew J.","family":"Mungall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-3108","authenticated-orcid":false,"given":"Elena","family":"Zaikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-4311","authenticated-orcid":false,"given":"Esther","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-6323","authenticated-orcid":false,"given":"Daniel","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza S.","family":"Malbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Marton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Manaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Winterkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gelmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-0012","authenticated-orcid":false,"given":"Margaret K.","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7522-6173","authenticated-orcid":false,"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Potenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-2222","authenticated-orcid":false,"given":"Jedd D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-136X","authenticated-orcid":false,"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-4741","authenticated-orcid":false,"given":"Marcin","family":"Imielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5000","authenticated-orcid":false,"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-9599","authenticated-orcid":false,"given":"Sam","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-9945","authenticated-orcid":false,"given":"Nasser K.","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":false,"given":"Michael A.","family":"Postow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5698-8183","authenticated-orcid":false,"given":"Nicolas","family":"Robine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7406-2103","authenticated-orcid":false,"given":"Claus Lindbjerg","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2346-9541","authenticated-orcid":false,"given":"Dan A.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"3040_CR1","doi-asserted-by":"publisher","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature https:\/\/doi.org\/10.1038\/s41586-021-03642-9 (2021).","DOI":"10.1038\/s41586-021-03642-9"},{"key":"3040_CR2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873\u2013881 (2020).","journal-title":"Nat. Cancer"},{"key":"3040_CR3","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3040_CR4","doi-asserted-by":"publisher","unstructured":"Phallen, J. et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aan2415 (2017).","DOI":"10.1126\/scitranslmed.aan2415"},{"key":"3040_CR5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548\u2013554 (2014).","journal-title":"Nat. Med."},{"key":"3040_CR6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363\u2013376 (2020).","journal-title":"Cell"},{"key":"3040_CR7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24109-5","volume":"12","author":"A Rose Brannon","year":"2021","unstructured":"Rose Brannon, A. et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat. Commun. 12, 3770 (2021).","journal-title":"Nat. Commun."},{"key":"3040_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua, M. J. M. et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann. Oncol. 32, 229\u2013239 (2021).","journal-title":"Ann. Oncol."},{"key":"3040_CR9","doi-asserted-by":"publisher","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2404 (2021).","DOI":"10.1158\/1078-0432.CCR-21-2404"},{"key":"3040_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."},{"key":"3040_CR11","doi-asserted-by":"publisher","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-021-00981-w (2021).","DOI":"10.1038\/s41587-021-00981-w"},{"key":"3040_CR12","doi-asserted-by":"publisher","unstructured":"Haque, I. S. & Elemento, O. Challenges in using ctDNA to achieve early detection of cancer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/237578 (2017).","DOI":"10.1101\/237578"},{"key":"3040_CR13","doi-asserted-by":"crossref","first-page":"eabc4308","DOI":"10.1126\/sciadv.abc4308","volume":"6","author":"S Avanzini","year":"2020","unstructured":"Avanzini, S. et al. A mathematical model of ctDNA shedding predicts tumor detection size. Sci. Adv. 6, eabc4308 (2020).","journal-title":"Sci. Adv."},{"key":"3040_CR14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","volume":"26","author":"A Zviran","year":"2020","unstructured":"Zviran, A. et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat. Med. 26, 1114\u20131124 (2020).","journal-title":"Nat. Med."},{"key":"3040_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman, A. M. et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547\u2013555 (2016).","journal-title":"Nat. Biotechnol."},{"key":"3040_CR16","doi-asserted-by":"publisher","unstructured":"Wan, J. C. M. et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz8084 (2020).","DOI":"10.1126\/scitranslmed.aaz8084"},{"key":"3040_CR17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41551-022-00855-9","volume":"6","author":"G Gydush","year":"2022","unstructured":"Gydush, G. et al. Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nat. Biomed. Eng. 6, 257\u2013266 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"3040_CR18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"3040_CR19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","volume":"354","author":"LB Alexandrov","year":"2016","unstructured":"Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354, 618\u2013622 (2016).","journal-title":"Science"},{"key":"3040_CR20","doi-asserted-by":"crossref","first-page":"e1006162","DOI":"10.1371\/journal.pgen.1006162","volume":"12","author":"HR Underhill","year":"2016","unstructured":"Underhill, H. R. et al. Fragment length of circulating tumor DNA. PLoS Genet. 12, e1006162 (2016).","journal-title":"PLoS Genet."},{"key":"3040_CR21","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","volume":"10","author":"F Mouliere","year":"2018","unstructured":"Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10, eaat4921 (2018).","journal-title":"Sci. Transl. Med."},{"key":"3040_CR22","volume":"21","author":"J Guo","year":"2020","unstructured":"Guo, J. et al. Quantitative characterization of tumor cell-free DNA shortening. BMC Genomics 21, 473 (2020).","journal-title":"BMC Genomics"},{"key":"3040_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cell.2019.02.051","volume":"177","author":"A Gonzalez-Perez","year":"2019","unstructured":"Gonzalez-Perez, A., Sabarinathan, R. & Lopez-Bigas, N. Local determinants of the mutational landscape of the human genome. Cell 177, 101\u2013114 (2019).","journal-title":"Cell"},{"key":"3040_CR24","volume":"3","author":"YH Woo","year":"2012","unstructured":"Woo, Y. H. & Li, W.-H. DNA replication timing and selection shape the landscape of nucleotide variation in cancer genomes. Nat. Commun. 3, 1004 (2012).","journal-title":"Nat. Commun."},{"key":"3040_CR25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cell.2015.12.050","volume":"164","author":"NJ Haradhvala","year":"2016","unstructured":"Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538\u2013549 (2016).","journal-title":"Cell"},{"key":"3040_CR26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2013.01.001","volume":"23","author":"N Donley","year":"2013","unstructured":"Donley, N. & Thayer, M. J. DNA replication timing, genome stability and cancer: late and\/or delayed DNA replication timing is associated with increased genomic instability. Semin. Cancer Biol. 23, 80\u201389 (2013).","journal-title":"Semin. Cancer Biol."},{"key":"3040_CR27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature14221","volume":"518","author":"P Polak","year":"2015","unstructured":"Polak, P. et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518, 360\u2013364 (2015).","journal-title":"Nature"},{"key":"3040_CR28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41588-023-01446-3","volume":"55","author":"DC Bruhm","year":"2023","unstructured":"Bruhm, D. C. et al. Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer. Nat. Genet. 55, 1301\u20131310 (2023).","journal-title":"Nat. Genet."},{"key":"3040_CR29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676\u2013689.e3 (2018).","journal-title":"Cancer Cell"},{"key":"3040_CR30","doi-asserted-by":"publisher","unstructured":"Deshpande, A., Walradt, T., Hu, Y., Koren, A. & Imielinski, M. Robust foreground detection in somatic copy number data. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/847681 (2019).","DOI":"10.1101\/847681"},{"key":"3040_CR31","doi-asserted-by":"crossref","first-page":"15.9.1","DOI":"10.1002\/cpbi.17","volume":"56","author":"KM Raine","year":"2016","unstructured":"Raine, K. M. et al. AscatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr. Protoc. Bioinform. 56, 15.9.1\u201315.9.17 (2016).","journal-title":"Curr. Protoc. Bioinform."},{"key":"3040_CR32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"3040_CR33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385\u2013389 (2019).","journal-title":"Nature"},{"key":"3040_CR34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57\u201368 (2016).","journal-title":"Cell"},{"key":"3040_CR35","first-page":"E10925","volume":"115","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 115, E10925\u2013E10933 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3040_CR36","doi-asserted-by":"publisher","unstructured":"Renaud, G. et al. Unsupervised detection of fragment length signatures of circulating tumor DNA using non-negative matrix factorization. eLife https:\/\/doi.org\/10.7554\/eLife.71569 (2022).","DOI":"10.7554\/eLife.71569"},{"key":"3040_CR37","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ng.2760","volume":"45","author":"TI Zack","year":"2013","unstructured":"Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134\u20131140 (2013).","journal-title":"Nat. Genet."},{"key":"3040_CR38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"3040_CR39","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1158\/1538-7445.AM2022-5114","volume":"82","author":"AC Tan","year":"2022","unstructured":"Tan, A. C. et al. Abstract 5114: ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC). Cancer Res. 82, 5114 (2022).","journal-title":"Cancer Res."},{"key":"3040_CR40","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie, J. et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5, 1710\u20131717 (2019).","journal-title":"JAMA Oncol."},{"key":"3040_CR41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","volume":"22","author":"NK Altorki","year":"2021","unstructured":"Altorki, N. K. et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 22, 824\u2013835 (2021).","journal-title":"Lancet Oncol."},{"key":"3040_CR42","doi-asserted-by":"crossref","first-page":"19368","DOI":"10.18632\/oncotarget.25053","volume":"9","author":"S-I Kageyama","year":"2018","unstructured":"Kageyama, S.-I. et al. Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Oncotarget 9, 19368\u201319378 (2018).","journal-title":"Oncotarget"},{"key":"3040_CR43","first-page":"562","volume":"40","author":"J Shaw","year":"2022","unstructured":"Shaw, J. et al. Serial postoperative ctDNA monitoring of breast cancer recurrence. J. Clin. Orthod. 40, 562 (2022).","journal-title":"J. Clin. Orthod."},{"key":"3040_CR44","volume":"9","author":"NNM Myint","year":"2018","unstructured":"Myint, N. N. M. et al. Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death Dis. 9, 894 (2018).","journal-title":"Cell Death Dis."},{"key":"3040_CR45","doi-asserted-by":"publisher","unstructured":"Junca, A. et al. Detection of colorectal cancer and advanced adenoma by liquid biopsy (Decalib Study): the ddPCR challenge. Cancers https:\/\/doi.org\/10.3390\/cancers12061482 (2020).","DOI":"10.3390\/cancers12061482"},{"key":"3040_CR46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.21873\/anticanres.11360","volume":"37","author":"M Galanopoulos","year":"2017","unstructured":"Galanopoulos, M. et al. Comparative study of mutations in single nucleotide polymorphism loci of KRAS and BRAF genes in patients who underwent screening colonoscopy, with and without premalignant intestinal polyps. Anticancer Res. 37, 651\u2013657 (2017).","journal-title":"Anticancer Res."},{"key":"3040_CR47","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2196\/resprot.6346","volume":"5","author":"L Rasmussen","year":"2016","unstructured":"Rasmussen, L. et al. Protocol outlines for parts 1 and 2 of the prospective endoscopy III study for the early detection of colorectal cancer: validation of a concept based on blood biomarkers. JMIR Res. Protoc. 5, e182 (2016).","journal-title":"JMIR Res. Protoc."},{"key":"3040_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4321\/S1130-01082005000100002","volume":"97","author":"M Alc\u00e1ntara Torres","year":"2005","unstructured":"Alc\u00e1ntara Torres, M. et al. DNA aneuploidy in colorectal adenomas. Role in the adenoma-carcinoma sequence. Rev. Esp. Enferm. Dig. 97, 7\u201315 (2005).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"3040_CR49","volume":"13","author":"Y Lin","year":"2018","unstructured":"Lin, Y. et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat. Oncol. 13, 177 (2018).","journal-title":"Radiat. Oncol."},{"key":"3040_CR50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/gcc.22539","volume":"57","author":"RK Wolff","year":"2018","unstructured":"Wolff, R. K. et al. Mutation analysis of adenomas and carcinomas of the colon: early and late drivers. Genes Chromosomes Cancer 57, 366\u2013376 (2018).","journal-title":"Genes Chromosomes Cancer"},{"key":"3040_CR51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25432-7","volume":"12","author":"SY Cindy Yang","year":"2021","unstructured":"Cindy Yang, S. Y. et al. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat. Commun. 12, 5137 (2021).","journal-title":"Nat. Commun."},{"key":"3040_CR52","doi-asserted-by":"publisher","unstructured":"Postow, M. A. et al. Adaptive dosing of nivolumab + ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (The ADAPT-IT Study). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.21.01570 (2021).","DOI":"10.1200\/JCO.21.01570"},{"key":"3040_CR53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).","journal-title":"Nat. Commun."},{"key":"3040_CR54","doi-asserted-by":"publisher","unstructured":"Weber, S. et al. Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non\u2013small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.21.00182 (2021).","DOI":"10.1200\/PO.21.00182"},{"key":"3040_CR55","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0047 (2020).","DOI":"10.1158\/2159-8290.CD-20-0047"},{"key":"3040_CR56","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3040_CR57","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai, X. et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin. Cancer Res. 27, 5993\u20136000 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3040_CR58","doi-asserted-by":"publisher","unstructured":"Almogy, G. et al. Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.05.29.493900 (2022).","DOI":"10.1101\/2022.05.29.493900"},{"key":"3040_CR59","doi-asserted-by":"publisher","unstructured":"Chowell, D. et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-021-01070-8 (2021).","DOI":"10.1038\/s41587-021-01070-8"},{"key":"3040_CR60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-019-1907-7","volume":"578","author":"M Gerstung","year":"2020","unstructured":"Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122\u2013128 (2020).","journal-title":"Nature"},{"key":"3040_CR61","unstructured":"Illumina. TruSeq DNA PCR-Free Reference Guide (Illumina, 2017)."},{"key":"3040_CR62","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","volume":"65","author":"T Reinert","year":"2016","unstructured":"Reinert, T. et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65, 625\u2013634 (2016).","journal-title":"Gut"},{"key":"3040_CR63","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"3040_CR64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2105-15-182","volume":"15","author":"H Jiang","year":"2014","unstructured":"Jiang, H., Lei, R., Ding, S.-W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinform. 15, 182 (2014).","journal-title":"BMC Bioinform."},{"key":"3040_CR65","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1093\/bioinformatics\/btw389","volume":"32","author":"EA Bergmann","year":"2016","unstructured":"Bergmann, E. A., Chen, B.-J., Arora, K., Vacic, V. & Zody, M. C. Conpair: concordance and contamination estimator for matched tumor-normal pairs. Bioinformatics 32, 3196\u20133198 (2016).","journal-title":"Bioinformatics"},{"key":"3040_CR66","volume":"9","author":"K Arora","year":"2019","unstructured":"Arora, K. et al. Deep whole-genome sequencing of 3 cancer cell lines on 2 sequencing platforms. Sci. Rep. 9, 19123 (2019).","journal-title":"Sci. Rep."},{"key":"3040_CR67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol."},{"key":"3040_CR68","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"3040_CR69","volume":"9","author":"HM Amemiya","year":"2019","unstructured":"Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE blacklist: identification of problematic regions of the genome. Sci. Rep. 9, 9354 (2019).","journal-title":"Sci. Rep."},{"key":"3040_CR70","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"3040_CR71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium.","year":"2012","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374 (2012).","journal-title":"Nature"},{"key":"3040_CR72","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nbt.1518","volume":"27","author":"J Rozowsky","year":"2009","unstructured":"Rozowsky, J. et al. PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls. Nat. Biotechnol. 27, 66\u201375 (2009).","journal-title":"Nat. Biotechnol."},{"key":"3040_CR73","doi-asserted-by":"crossref","first-page":"eaav1898","DOI":"10.1126\/science.aav1898","volume":"362","author":"MR Corces","year":"2018","unstructured":"Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, eaav1898 (2018).","journal-title":"Science"},{"key":"3040_CR74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nmeth.1906","volume":"9","author":"J Ernst","year":"2012","unstructured":"Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods 9, 215\u2013216 (2012).","journal-title":"Nat. Methods"},{"key":"3040_CR75","volume":"10","author":"K Xiong","year":"2019","unstructured":"Xiong, K. & Ma, J. Revealing Hi-C subcompartments by imputing inter-chromosomal chromatin interactions. Nat. Commun. 10, 5069 (2019).","journal-title":"Nat. Commun."},{"key":"3040_CR76","unstructured":"Imielinski, M. et al. fragCounter: GC and mappability corrected fragment coverage for paired end whole genome sequencing. GitHub https:\/\/github.com\/mskilab-org\/fragCounter (2018)."},{"key":"3040_CR77","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nmeth.3582","volume":"12","author":"B van de Geijn","year":"2015","unstructured":"van de Geijn, B., McVicker, G., Gilad, Y. & Pritchard, J. K. WASP: allele-specific software for robust molecular quantitative trait locus discovery. Nat. Methods 12, 1061\u20131063 (2015).","journal-title":"Nat. Methods"},{"key":"3040_CR78","doi-asserted-by":"publisher","unstructured":"Dentro, S. C., Wedge, D. C. & Van Loo, P. Principles of reconstructing the subclonal architecture of cancers. Cold Spring Harb. Perspect. Med. https:\/\/doi.org\/10.1101\/cshperspect.a026625 (2017).","DOI":"10.1101\/cshperspect.a026625"},{"key":"3040_CR79","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/clinchem\/hvab274","volume":"68","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Error characterization and statistical modeling improves circulating tumor DNA detection by droplet digital PCR. Clin. Chem. 68, 657\u2013667 (2022).","journal-title":"Clin. Chem."},{"key":"3040_CR80","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1002\/1878-0261.13294","volume":"16","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients. Mol. Oncol. 16, 3654\u20133665 (2022).","journal-title":"Mol. Oncol."},{"key":"3040_CR81","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"3040_CR82","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3040_CR83","doi-asserted-by":"publisher","unstructured":"Davidson-Pilon, C. lifelines, survival analysis in Python. Zenodo https:\/\/doi.org\/10.5281\/zenodo.5512044 (2021).","DOI":"10.5281\/zenodo.5512044"},{"key":"3040_CR84","doi-asserted-by":"publisher","unstructured":"Zivich, P., Davidson-Pilon, C., Reger, D., Diong, J. & The Gitter Badger. pzivich\/zEpid: v.0.9.0. Zenodo https:\/\/doi.org\/10.5281\/zenodo.7234506 (2020).","DOI":"10.5281\/zenodo.7234506"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03040-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03040-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03040-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T10:21:47Z","timestamp":1718792507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03040-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3040"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03040-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.17.476508","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.L., A.J.W., C.C.K. and J.B. are listed as inventors on a pending patent application (WO2023018791A1), filed by Cornell University, which is directed to methods of detecting SNVs for the purposes of MRD detection and other plasma-based cancer monitoring. D.A.L., A.J.W. and M.S. are listed as inventors on a pending patent application (WO2023133093A1), filed by Cornell University, which is directed to methods of detecting CNVs for the purposes of MRD detection and other plasma-based cancer monitoring. A.P.C. is listed as an inventor on submitted patents pertaining to cell-free DNA (US patent applications 63\/237,367, 63\/056,249, 63\/015,095 and 16\/500,929) and receives consulting fees from Eurofins Viracor. A.S. receives research funding from AstraZeneca, has served on Advisory Boards for AstraZeneca, Blueprint Medicines and Jazz Pharmaceuticals, and has been a consultant for Genentech. M.A.P. has received consulting fees from BMS, Chugai, Cancer Expert Now, Intellisphere, Merck, MJH Associates, Nektar, Pfizer, Uptodate, WebMD and Erasca, and received institutional support from RGenix, Infinity, BMS, Merck, Genentech and Novartis. C.L.A. reports collaborations with C2i Genomics and Natera. C.S. has received honoraria for advisory board participation from Pfizer, Novartis, Knight, Bayer, Merck, Roche and Lilly within the past 2 years. None of the honoraria has been in excess of CAD$5,000 and total for honoraria received is less than CAD$25,000. M.K.C. has received consulting fees from BMS, Merck, InCyte, Moderna, ImmunoCore and AstraZeneca and receives institutional support from BMS. S.T. is funded by Cancer Research UK (grant ref. no. A29911); the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC10988), the UK Medical Research Council (FC10988) and the Wellcome Trust (FC10988); the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant ref. no. A109), the Royal Marsden Cancer Charity, The Rosetrees Trust (grant ref. no. A2204), Ventana Medical Systems (grant reference nos. 10467 and 10530), the National Institute of Health (U01 CA247439) and Melanoma Research Alliance (award ref. no. 686061). S.T. has received speaking fees from Roche, AstraZeneca, Novartis and Ipsen. S.T. has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018\/051892 and PCTGB2018\/051893. G.B. has sponsored research agreements through her institution with: Olink Proteomics, Teiko Bio, InterVenn Biosciences and Palleon Pharmaceuticals. G.B. served on advisory boards for Iovance, Merck, Nektar Therapeutics, Novartis and Ankyra Therapeutics. G.B. consults for Merck, InterVenn Biosciences, Iovance and Ankyra Therapeutics. G.B. holds equity in Ankyra Therapeutics. M.F.B. reports consulting for AstraZeneca, Eli Lilly, Paige.AI, research support from Boundless Bio and intellectual property rights for SOPHiA Genetics. J.D.W. is a consultant for Apricity, Ascentage Pharma, AstraZeneca, BeiGene, Bicara Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, Dragonfly, Imvaq, Larkspur, Psioxus, Recepta, Takeda, Tizona, Trishula Therapeutics and Sellas. J.D.W. received grant\/research support from Bristol Myers Squibb and Enterome. J.D.W. has Equity in Apricity, Arsenal IO\/CellCarta, Ascentage, Imvaq, Linneaus, Larkspur, Georgiamune, Maverick, Tizona Therapeutics and Xenimmune. D.A.L. received research support from Illumina. D.A.L. participated in advisory boards Pangea, Mission Bio and Alethiomics. D.A.L. is a scientific co-founder of C2i Genomics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}